Combination BRAFV600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAFV600E-Mutant Anaplastic Thyroid Cancer-Reference-Cited by-同舟云学术

Combination BRAF^V600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAF^V600E-Mutant Anaplastic Thyroid Cancer

Published:2023-10-01 Issue:10 Volume:33 Page:1201-1214
ISSN:1050-7256
Container-title:Thyroid®
language:en
Short-container-title:Thyroid®

Author:

Gunda Viswanath¹,Ghosh Chandrayee¹^ORCID,Hu Jiangnan¹,Zhang Lisa²,Zhang Ya qin³,Shen Min³,Kebebew Electron¹⁴^ORCID

Affiliation:

1. Department of Surgery, Stanford University, Stanford, California, USA.

2. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.

3. National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA.

4. Stanford Cancer Institute, Stanford University, Stanford, California, USA.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2023.0201

Reference59 articles.

1. Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment

2. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

3. Multimodality therapeutic outcomes In anaplastic thyroid carcinoma: Improved survival in subgroups of patients with localized primary tumors

4. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases

5. Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics–Pharmacodynamics Modeling for Evaluating Drug–Drug Interactions in Polypharmacy: Development and Challenges;Clinical Pharmacokinetics;2024-06-18

2. Research progress in MCM family: Focus on the tumor treatment resistance;Biomedicine & Pharmacotherapy;2024-04

3. Advances in targeted therapy and biomarker research in thyroid cancer;Frontiers in Endocrinology;2024-03-04

4. Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers;Receptors;2024-03-04

5. Study on the Targeted Drugs for the Treatment of Thyroid Cancer Based on Network Pharmacology;Advances in Clinical Medicine;2024